VANCOUVER, British Columbia, May 30, 2024–(BUSINESS WIRE)–Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) (“Lobe” or the “Company”), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Dr. Harry Jacobson has agreed to join its Board of Directors in the coming months.
Dr. Jacobson brings over three decades of distinguished experience in healthcare, biotechnology, and medical innovation. As a serial entrepreneur, executive and visionary leader, his extensive knowledge and strategic insights will be invaluable to Lobe Sciences as the company continues to pioneer groundbreaking treatments and expand its footprint in the development of transformative medicines for orphan and rare diseases.
“We are thrilled to welcome Dr. Jacobson to our Board of Directors,” said Philip J. Young, Chairman and CEO of Lobe Sciences. “Dr. Jacobson’s remarkable track record in healthcare and his passion for advancing medical science align perfectly with our mission to transform the development of treatments for neurologic diseases. His expertise will be instrumental as we navigate the evolving landscape to develop and commercialize our lead programs for Chronic Cluster Headaches and Sickle Cell Disease.”
Board certified in Internal Medicine and Nephrology, Dr. Jacobson joined Vanderbilt Medical Faculty in 1985 as Professor of Medicine and Director of the Division of Nephrology. After developing one of the nation’s premier nephrology divisions, Dr. Jacobson was named Vice Chancellor for Health Affairs and CEO of the Vanderbilt University Medical Center (VUMC).
As Vice Chancellor for Health Affairs, Dr. Jacobson’s 12-year tenure saw the VUMC budget expand from $750M to $2.5B, all the while delivering superior care. Vanderbilt’s federally funded research moved from 24th to top 10 in the country and more than $1B of newly constructed facilities were opened. Among these projects are the Monroe Carell Children’s Hospital and Vanderbilt Health at 100 Oaks.
During the course of his career, Dr. Jacobson has been a successful investor and entrepreneur, having founded or co-founded several companies, including Contact Software, the developer of the software program ACT which helped launch the CRM software category; Renal Care Group; Cardiovascular Care Group; Informatics Corporation of America; CeloNova Biosciences, Ambulatory Services of America; MindCare Solutions; Innovative Renal Care; MedLogic, and For Better Health (4BH). He has served on the boards of three New York Stock Exchange companies including Merck, Kinetic Concepts, and Renal Care Group. Currently, Dr. Jacobson serves on the Board of Directors of several healthcare companies from the original MedCare portfolio. In 2013, Dr. Jacobson served Belmont’s Jack C. Massey Graduate School of Business as its Distinguished Healthcare Executive-in-Residence and was Chairman of the McWhorter Society from 2014 to 2017.
“I am excited to join Lobe Sciences at such a pivotal time in the company’s growth,” said Dr. Jacobson. “The potential of their neurologic and Sickle Cell Programs to change the lives of patients around the globe is inspiring and I look forward to working with the talented team at Lobe Sciences to advance their promising pipeline of therapies.”
Lobe Sciences is a biopharmaceutical company focused on developing transformative medicines to treat rare diseases. The Company, through collaborations with industry-leading partners, is additionally engaged in drug research and development using non-hallucinatory doses of stabilized psilocin based compounds to address unmet medical needs in orphan neurological therapeutic applications.